2 Einträge gefunden

1. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study

   1. Pivot, X
   2. Verma, S
   3. Fallowfield, L
   4. Müller, V
   5. Lichinitser, M
   6. Jenkins, V
   7. Sánchez Muñoz, A

   2017 - Forschungsinformationssystem des UKE
2. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

   1. Pivot, X
   2. Gligorov, J
   3. Müller, V
   4. Curigliano, G
   5. Knoop, A
   6. Verma, S
   7. Jenkins, V

   2014 - Forschungsinformationssystem des UKE